CMS allows reimbursement for Spectrum cancer drug Zevalin

11/4/2009 | Reuters

The CMS approved reimbursement for Spectrum Pharmaceuticals' non-Hodgkin's lymphoma drug Zevalin, effective Jan. 1. The ruling removes "a significant historical barrier" to use of the drug, CEO Rajesh Shrotriya said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care